Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose Psilocybin for Post-surgical Trauma Inpatients with OUD
NCT07406828Phase 1Not yet recruiting
- Start
- Dec 2027
- Primary completion
- Apr 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of psilocybin in postoperative pain and opioid use disorder (OUD) (2 arms). Primary endpoints: Feasibility: Recruitment at 3 days, Feasibility: Retention at 5 days and 1 more. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
postoperative painopioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07406828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406828.